JACOBS LEVY EQUITY MANAGEMENT, INC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$26,676,111
-4.3%
748,278
+23.8%
0.16%
-1.9%
Q2 2023$27,875,759
-10.4%
604,287
-22.1%
0.16%
-15.7%
Q1 2023$31,108,578
+1.6%
775,775
+17.3%
0.19%
-7.7%
Q4 2022$30,627,976
+234.8%
661,083
+199.3%
0.21%
+187.5%
Q3 2022$9,147,000
+3679.8%
220,880
+7580.1%
0.07%
+3500.0%
Q4 2021$242,000
-75.3%
2,876
-75.8%
0.00%
-80.0%
Q3 2020$978,000
-53.4%
11,898
-55.6%
0.01%
-56.5%
Q2 2020$2,097,000
+383.2%
26,806
+174.2%
0.02%
+283.3%
Q1 2020$434,000
+80.1%
9,777
+106.7%
0.01%
+50.0%
Q1 2018$241,0004,7300.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 519,119$40,605,0003.00%
First Light Asset Management, LLC 236,958$18,535,0002.16%
SECTOR GAMMA AS 108,734$8,505,0001.76%
Rock Springs Capital Management LP 646,841$50,596,0001.39%
Atika Capital Management LLC 79,000$6,180,0000.80%
Capital Impact Advisors, LLC 30,582$2,392,0000.80%
FEDERATED HERMES, INC. 4,080,359$319,166,0000.79%
Rhenman & Partners Asset Management AB 61,500$4,811,0000.52%
Ikarian Capital, LLC 73,500$5,749,0000.46%
Capital International, Inc./CA/ 477,858$37,378,0000.46%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders